单克隆免疫球蛋白沉积性增生性肾小球肾炎:肾内科视角
单克隆免疫球蛋白沉积性增生性肾小球肾炎(PGNMID)是单克隆丙种球蛋白肾病意义(MGRS)谱系中肾脏受限的疾病,多表现为慢性肾小球病、肾功能异常和蛋白尿,急性肾炎综合征罕见。诊断依赖免疫荧光和电镜显示仅肾小球内单型IgG沉积(常见IgG3及κ轻链限制),血清/尿检出肾毒性单克隆Ig及骨髓B细胞克隆的比率仅约30%。肾脏预后差,25%患者30个月内进展至终末期肾病,移植后早期复发常见;克隆靶向化疗可能改善肾脏结局。
要点
- PGNMID诊断依赖免疫荧光和电镜显示肾小球单型IgG沉积伴轻链限制。
- 仅约30%患者可检出循环单克隆Ig或骨髓B细胞克隆,诊断需肾活检。
- 25%患者30个月内进展至终末期肾病,肾移植后早期复发频繁。
核心结论
- PGNMID是肾脏受限的MGRS病变,肾脏预后差,克隆靶向化疗可能改善肾脏结局。
研究设计与样本
- 综述,从肾内科视角总结PGNMID的临床病理特征、诊断与治疗。
主要发现
- PGNMID多发生于第六个十年,但也可影响年轻成人,表现为慢性肾小球病、肾功能异常和蛋白尿,有时达肾病范围,急性肾炎综合征罕见。
- 组织学以膜增生性肾小球肾炎为主,少数为弥漫性毛细血管内增生性、系膜增生性或非典型膜性肾小球肾炎。
- 免疫荧光和电镜显示颗粒状沉积物仅累及肾小球,由单型IgG组成,单一重链亚类(最常见IgG3)和轻链限制(通常κ),混有补体沉积。
- 仅轻链型、IgA或IgM沉积的变异型不常见;超微结构下沉积物无定形,主要分布于内皮下和系膜区。
- 血清或尿中检出肾毒性单克隆Ig及异常骨髓B细胞克隆的比率仅约30%。
关键数值与推荐
- PGNMID应与1型冷球蛋白血症性肾小球肾炎和免疫触须样肾小球病鉴别,它们有共同病理特征。
- 肾脏预后差,25%患者在30个月内进展至终末期肾病,肾移植后早期复发频繁。
临床怎么用
- 对表现为慢性肾小球病伴蛋白尿和肾功能异常的患者,应通过肾活检免疫荧光和电镜诊断PGNMID。
- 即使血清/尿单克隆Ig及骨髓克隆检出率低,仍应进行相关检查以指导克隆靶向治疗。
- 肾移植后需监测PGNMID早期复发。
局限性
- PGNMID的病理生理学尚不清楚,治疗仍具挑战性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Proliferative glomerulonephritis (GN) with monoclonal immunoglobulin deposits (PGNMIDs) is a recently described entity among the spectrum of monoclonal gammopathy of renal significance (MGRS). The disease is renal limited and manifests with chronic glomerular disease, altered renal function and albuminuria, sometimes in the nephrotic range. Acute nephritic syndrome is rare. PGNMID occurs mostly in the sixth decade, but it may affect young adults. Histologically, PGNMID is characterized predominantly by membranoproliferative GN and less frequently by diffuse endocapillary GN, mesangioproliferative GN or atypical membranous GN. Immunofluorescence and electron microscopic studies are the cornerstone of diagnosis, showing granular deposits involving glomeruli only, and composed of monotypic immunoglobulin G (IgG), with a single heavy chain subclass (most commonly IgG3) and light chain (LC) restriction (usually κ), admixed with complement deposits. PGNMID variants with monotypic LC-only, IgA or IgM deposits are uncommon. Ultrastructurally, deposits are amorphous with predominant subendothelial and mesangial distribution. PGNMID should be distinguished from type 1 cryoglobulinemic GN and immunotactoid GN, which share some common pathological features. Contrary to other MGRS lesions, the rate of detection of the nephrotoxic monoclonal Ig in the serum or urine, and of an abnormal bone marrow B-cell clone, is only ∼30%. Renal prognosis is poor, with progression to end-stage renal disease in 25% of patients within 30 months and frequent early recurrence on the renal allograft. The pathophysiology of PGNMID is unclear and its treatment remains challenging. However, recent studies indicate that clone-targeted chemotherapy may significantly improve renal outcomes, opening future perspectives for the management of this rare disease.
引用
- Bridoux F, Javaugue V, Nasr SH, et al. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective. Nephrol Dial Transplant. 2021. PMID: 33494099. doi:10.1093/ndt/gfz176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。